Cassava Sciences, Inc.

About Cassava Sciences, Inc.

Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing transformative medicines to improve the lives of patients with Central Nervous System (CNS) disorders. Their mission is driven by rigorous science, transparent communication, and meaningful partnerships with patients, caregivers, clinicians, and research collaborators.

Products & Services

Simufilam:A proprietary, investigational oral small molecule therapy believed to modulate the activity of the filamin A (FLNA) protein, targeting central nervous system disorders such as tuberous sclerosis complex (TSC)-related epilepsy and potentially other indications. Preclinical studies show it reduces seizure frequency by 60-70% in mouse models.

Specialties

Central Nervous System (CNS) disorders Tuberous Sclerosis Complex (TSC)-related epilepsy Novel investigational treatments mTOR pathway disorders

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 125000000 MR: - FA: over $125 million FAN: 125000000	D: 2024-05-08 FD: 2024-05-08	-

Warrant Exercise Latest

2024-05-08

$125.0M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard J. Barry

President & Chief Executive Officer

R

Robert Anderson, Jr.

Independent Director

P

Pierre Gravier

Independent Director

R

Robert Gussin

Independent Director

C

Claude Nicaise

Chairman of the Board

M

Michael O'Donnell

Independent Director

View 14 more team members with Pro

Unlock Full Team Directory

Recent News